Dendreon Corp (DNDN) 1.39 $DNDN
Medivation Eyes Blockbuster As Cancer Drug Gets An OK
at Investor's Business Daily - Thu Sep 11, 4:41PM CDT
Two years ago, biotech Medivation launched its first drug -- an achievement that put it ahead of more than half the biotechs trading on the market. But as of Wednesday afternoon, as far as Wall Street was concerned, it became more than just another...
Medivation Inc's FDA Approval Could be the Deathblow for Johnson & Johnson's Blockbuster Prostate Ca
Brian Orelli, The Motley Fool - Motley Fool - Wed Sep 10, 8:42PM CDT
Johnson & Johnson 's sold over $1 billion worth of its prostate cancer drug Zytiga in the first half of the year, putting it on pace to be a blockbuster two times over . But not if Medivation and partner Astellas Pharma have anything to...
Global Cancer Vaccines Market & Pipeline Analysis Report 2014: 12 Marketed Vaccines & 289 Pipeline Vaccines
M2 - Mon Sep 08, 10:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nnd4k6/global_cancer) has announced the addition of the "Global Cancer Vaccines Market & Pipeline Analysis" report to their offering. Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized. Therapeutic or Treatment vaccines are targeted at treating an existing cancer by strengthening the body's natural defences against the cancer and the Prophylactic or Preventive vaccines are used to prevent cancer from developing in healthy people. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. With the increasing focus of pharmaceutical companies in the cancer vaccine segment, the prophylactic vaccines segment grew substantially and currently is the largest source of revenue, with the therapeutic vaccines segment still remaining untapped. It is most likely that the regulatory authorities would in the near future quicken its approval process specifically for therapeutic vaccines. This coupled with a significant amount of investment for the research and development of these vaccines by the pharmaceutical companies would certainly push the overall cancer vaccines market onto a rapid growth trajectory. The current market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category. Global Cancer Vaccines Market & Pipeline Analysis" Report Highlights: - Global Cancer Market Overview - Personalized Cancer Vaccines: Progress & Possibilities - Platforms for Cancer Vaccines Delivery - Cancer Vaccines: Mechanism & Innovations - Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country - Global Cancer Vaccine Clinical Pipeline: 289 Vaccines - Marketed Cancer Vaccines: 12 Vaccines - Regulatory Framework for Cancer Vaccines Development & Marketing Key Topics Covered: 1. Introduction to Cancer Vaccines 2. Cancer Vaccines: Mechanism & Innovations 3. Adjuvants Platforms for Cancer Vaccines Delivery 4. Global Cancer Vaccines Market Overview 5. Personalized Cancer Vaccines: Progress & Possibilities 6. Public HPV Cancer Vaccination Program 7. Global Cancer Vaccines Market Dynamics 8. Future Prospects of Cancer Vaccines 9. Global Cancer Vaccines Clinical Pipeline Insight by Phase, Indication, Company & Country 10. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country 11. Suspended & Discontinued Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country 12. FDA Regulatory Framework for Cancer Vaccines Development & Marketing 13. Competitive Landscape: Business Overview & Product Pipeline - Advaxis - Celldex Therapeutics - Dendreon Corporation - Galena Biopharma - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - Merck - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Novartis - Peregrine Pharmaceuticals - Roche - Seattle Genetics For more information visit http://www.researchandmarkets.com/research/nn...bal_cancer
SPDR(R) S&P Biotech ETF Receives Settlement Payment
Business Wire - Mon Aug 18, 3:00PM CDT
State Street Global Advisors announced today that the SPDR(R) S&P Biotech ETF (NYSE: XBI- News) received payment as an authorized claimant from a class action settlement related to Dendreon, Corp.
Aug. 18 Premarket Briefing: 10 Things You Should Know
at The Street - Mon Aug 18, 5:47AM CDT
U.S. stock futures rise as European stocks stage a recovery; Dollar General offers to buy Family Dollar for $9.7 billion; Tesla extends warranty on Model S sedan.
Ebola Vaccine and Inhaled Insulin Incoming
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat Aug 16, 5:01AM CDT
In this healthcare-focused of episode of Where The Money Is, analysts David Williamson and Michael Douglass tackle the weeks biggest stories in pharma and biotech, and how the industry is attempting to combat the Ebola Outbreak. MannKind's big news...
Dendreon Down on Default Risk, Reports Narrower Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 1:37PM CDT
Shares of Dendreon Corporation (DNDN) were down significantly after the company warned that it will not be able to repay or refinance its notes due 2016.
Kate Spade and Flowers Foods are big market movers
AP - Tue Aug 12, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
Most active Nasdaq-traded stocks
AP - Tue Aug 12, 12:48PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
Why Dendreon Corporation Stock Slumped Today
Michael Douglass, The Motley Fool - Motley Fool - Tue Aug 12, 9:46AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: In its latest 10-Q, filed yesterday, cancer drug...
Why Dendreon (DNDN) Stock Hit a One-Year Low Today
at The Street - Tue Aug 12, 9:04AM CDT
Dendreon (DNDN) plunged to a 52-week low of $1.33 on Tuesday after the company warned of it may not be able to pay its debt that matures in 2016.
Dendreon Warns Debt Bomb Might Wipe Out Shareholders
at The Street - Tue Aug 12, 6:17AM CDT
The struggling Provenge peddler is suffocating under $620 million in debt and the bill comes soon.
Biotech Equities Technical Momentum -- InterMune, Biogen Idec, Insmed, Dendreon, and Alexion Pharma
PR Newswire - Mon Aug 11, 7:40AM CDT
The trading session on Friday, August 08, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,553.93, up 1.13% and the NASDAQ Composite closed at 4,370.90, up 0.83%. The S&P 500 finished the day 1.15% higher at 1,931.59. The gains were broad based as all the ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 699.99, up 1.14%, and the index has advanced 4.73% in the previous three months. Investor-Edge has initiated coverage on the following equities: InterMune Inc. (NASDAQ: ITMN), Biogen Idec Inc. (NASDAQ: BIIB), Insmed Inc. (NASDAQ: INSM), Dendreon Corp. (NASDAQ: DNDN), and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). Free research on these five companies can be accessed at:
Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.
Dendreon Names W. Thomas Amick President and Chief Executive Officer
Business Wire - Wed Jul 30, 3:02PM CDT
Dendreon Corporation (Nasdaq
NDN) today announced that its board of directors has appointed W. Thomas Amick as president and chief executive officer, effective immediately. Mr. Amick has also been appointed to the Company's board of directors. Mr. Amick succeeds John H. Johnson, who previously announced his plans to step down as president and chief executive officer for personal reasons. Mr. Johnson will work with Mr. Amick through August 15, 2014 to ensure a smooth transition.
Are Cancer Vaccines Worth an Investment?
Seth Robey, The Motley Fool - Motley Fool - Thu Jul 10, 8:30AM CDT
A report from Boston's Decision Resource Group last month suggested that the immuno-oncology drugs garnering excitement from patients, doctors, and investors could balloon into a $9 billion market by 2022. That would represent a 23.8% CAGR from the...
Technical Data on Health Care Sector Equities -- Research on Achillion Pharma, Novavax, Dendreon, and Exelixis
PR Newswire - Thu Jul 10, 6:00AM CDT
On Wednesday, July 09, 2014, the NASDAQ Composite ended at 4,419.03, up 0.63%, the Dow Jones Industrial Average advanced 0.47%, to finish the day at 16,985.61, and the S&P 500 closed at 1,972.83, up 0.46%. The gains were broad based with nine out of ten sectors ending the session in positive. The S&P 500 Health Care Sector Index ended the day at 712.05, up 0.38%, with the index advancing 5.76% in the previous three months. Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Novavax Inc. (NASDAQ: NVAX), Dendreon Corp. (NASDAQ: DNDN) and Exelixis Inc. (NASDAQ: EXEL). Free technical research on ACHN, NVAX, DNDN and EXEL can be downloaded upon signing up at:
3 Reasons to Buy Medivation Inc.
George Budwell, The Motley Fool - Motley Fool - Mon Jul 07, 3:30PM CDT
The biotech industry has ballooned in terms of market value over the past two years. As a result, we have seen dozens of IPOs, creating a diverse population of companies that can be quite a challenge to follow in their entirety. So it's not...
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/465jcl/transitional_cell) has announced the addition of the "Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Amgen Inc. - Sanofi - Daiichi Sankyo Company, Limited - Novartis AG - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Dendreon Corporation - Cadila Pharmaceuticals Ltd. For more information visit http://www.researchandmarkets.com/research/46...ional_cell
Is There Any Hope for Dendreon?
Alexander Maxwell, The Motley Fool - Motley Fool - Wed Jul 02, 4:01PM CDT
Dendreon Corporation shareholders have been on a rollercoaster over the past few years. Dendreon got their lead product Provenge approved for use in metastatic castration-resistant prostate cancer, but has been unable to profitably produce and...
Medivation Eyes Blockbuster As Cancer Drug Gets An OK
at Investor's Business Daily - Thu Sep 11, 4:41PM CDT
Two years ago, biotech Medivation launched its first drug -- an achievement that put it ahead of more than half the biotechs trading on the market. But as of Wednesday afternoon, as far as Wall Street was concerned, it became more than just another...
Medivation Inc's FDA Approval Could be the Deathblow for Johnson & Johnson's Blockbuster Prostate Ca
Brian Orelli, The Motley Fool - Motley Fool - Wed Sep 10, 8:42PM CDT
Johnson & Johnson 's sold over $1 billion worth of its prostate cancer drug Zytiga in the first half of the year, putting it on pace to be a blockbuster two times over . But not if Medivation and partner Astellas Pharma have anything to...
Global Cancer Vaccines Market & Pipeline Analysis Report 2014: 12 Marketed Vaccines & 289 Pipeline Vaccines
M2 - Mon Sep 08, 10:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nnd4k6/global_cancer) has announced the addition of the "Global Cancer Vaccines Market & Pipeline Analysis" report to their offering. Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized. Therapeutic or Treatment vaccines are targeted at treating an existing cancer by strengthening the body's natural defences against the cancer and the Prophylactic or Preventive vaccines are used to prevent cancer from developing in healthy people. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. With the increasing focus of pharmaceutical companies in the cancer vaccine segment, the prophylactic vaccines segment grew substantially and currently is the largest source of revenue, with the therapeutic vaccines segment still remaining untapped. It is most likely that the regulatory authorities would in the near future quicken its approval process specifically for therapeutic vaccines. This coupled with a significant amount of investment for the research and development of these vaccines by the pharmaceutical companies would certainly push the overall cancer vaccines market onto a rapid growth trajectory. The current market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category. Global Cancer Vaccines Market & Pipeline Analysis" Report Highlights: - Global Cancer Market Overview - Personalized Cancer Vaccines: Progress & Possibilities - Platforms for Cancer Vaccines Delivery - Cancer Vaccines: Mechanism & Innovations - Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country - Global Cancer Vaccine Clinical Pipeline: 289 Vaccines - Marketed Cancer Vaccines: 12 Vaccines - Regulatory Framework for Cancer Vaccines Development & Marketing Key Topics Covered: 1. Introduction to Cancer Vaccines 2. Cancer Vaccines: Mechanism & Innovations 3. Adjuvants Platforms for Cancer Vaccines Delivery 4. Global Cancer Vaccines Market Overview 5. Personalized Cancer Vaccines: Progress & Possibilities 6. Public HPV Cancer Vaccination Program 7. Global Cancer Vaccines Market Dynamics 8. Future Prospects of Cancer Vaccines 9. Global Cancer Vaccines Clinical Pipeline Insight by Phase, Indication, Company & Country 10. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country 11. Suspended & Discontinued Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country 12. FDA Regulatory Framework for Cancer Vaccines Development & Marketing 13. Competitive Landscape: Business Overview & Product Pipeline - Advaxis - Celldex Therapeutics - Dendreon Corporation - Galena Biopharma - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - Merck - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Novartis - Peregrine Pharmaceuticals - Roche - Seattle Genetics For more information visit http://www.researchandmarkets.com/research/nn...bal_cancer
SPDR(R) S&P Biotech ETF Receives Settlement Payment
Business Wire - Mon Aug 18, 3:00PM CDT
State Street Global Advisors announced today that the SPDR(R) S&P Biotech ETF (NYSE: XBI- News) received payment as an authorized claimant from a class action settlement related to Dendreon, Corp.
Aug. 18 Premarket Briefing: 10 Things You Should Know
at The Street - Mon Aug 18, 5:47AM CDT
U.S. stock futures rise as European stocks stage a recovery; Dollar General offers to buy Family Dollar for $9.7 billion; Tesla extends warranty on Model S sedan.
Ebola Vaccine and Inhaled Insulin Incoming
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat Aug 16, 5:01AM CDT
In this healthcare-focused of episode of Where The Money Is, analysts David Williamson and Michael Douglass tackle the weeks biggest stories in pharma and biotech, and how the industry is attempting to combat the Ebola Outbreak. MannKind's big news...
Dendreon Down on Default Risk, Reports Narrower Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 1:37PM CDT
Shares of Dendreon Corporation (DNDN) were down significantly after the company warned that it will not be able to repay or refinance its notes due 2016.
Kate Spade and Flowers Foods are big market movers
AP - Tue Aug 12, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
Most active Nasdaq-traded stocks
AP - Tue Aug 12, 12:48PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
Why Dendreon Corporation Stock Slumped Today
Michael Douglass, The Motley Fool - Motley Fool - Tue Aug 12, 9:46AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: In its latest 10-Q, filed yesterday, cancer drug...
Why Dendreon (DNDN) Stock Hit a One-Year Low Today
at The Street - Tue Aug 12, 9:04AM CDT
Dendreon (DNDN) plunged to a 52-week low of $1.33 on Tuesday after the company warned of it may not be able to pay its debt that matures in 2016.
Dendreon Warns Debt Bomb Might Wipe Out Shareholders
at The Street - Tue Aug 12, 6:17AM CDT
The struggling Provenge peddler is suffocating under $620 million in debt and the bill comes soon.
Biotech Equities Technical Momentum -- InterMune, Biogen Idec, Insmed, Dendreon, and Alexion Pharma
PR Newswire - Mon Aug 11, 7:40AM CDT
The trading session on Friday, August 08, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,553.93, up 1.13% and the NASDAQ Composite closed at 4,370.90, up 0.83%. The S&P 500 finished the day 1.15% higher at 1,931.59. The gains were broad based as all the ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 699.99, up 1.14%, and the index has advanced 4.73% in the previous three months. Investor-Edge has initiated coverage on the following equities: InterMune Inc. (NASDAQ: ITMN), Biogen Idec Inc. (NASDAQ: BIIB), Insmed Inc. (NASDAQ: INSM), Dendreon Corp. (NASDAQ: DNDN), and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). Free research on these five companies can be accessed at:
Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.
Dendreon Names W. Thomas Amick President and Chief Executive Officer
Business Wire - Wed Jul 30, 3:02PM CDT
Dendreon Corporation (Nasdaq
NDN) today announced that its board of directors has appointed W. Thomas Amick as president and chief executive officer, effective immediately. Mr. Amick has also been appointed to the Company's board of directors. Mr. Amick succeeds John H. Johnson, who previously announced his plans to step down as president and chief executive officer for personal reasons. Mr. Johnson will work with Mr. Amick through August 15, 2014 to ensure a smooth transition. Are Cancer Vaccines Worth an Investment?
Seth Robey, The Motley Fool - Motley Fool - Thu Jul 10, 8:30AM CDT
A report from Boston's Decision Resource Group last month suggested that the immuno-oncology drugs garnering excitement from patients, doctors, and investors could balloon into a $9 billion market by 2022. That would represent a 23.8% CAGR from the...
Technical Data on Health Care Sector Equities -- Research on Achillion Pharma, Novavax, Dendreon, and Exelixis
PR Newswire - Thu Jul 10, 6:00AM CDT
On Wednesday, July 09, 2014, the NASDAQ Composite ended at 4,419.03, up 0.63%, the Dow Jones Industrial Average advanced 0.47%, to finish the day at 16,985.61, and the S&P 500 closed at 1,972.83, up 0.46%. The gains were broad based with nine out of ten sectors ending the session in positive. The S&P 500 Health Care Sector Index ended the day at 712.05, up 0.38%, with the index advancing 5.76% in the previous three months. Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Novavax Inc. (NASDAQ: NVAX), Dendreon Corp. (NASDAQ: DNDN) and Exelixis Inc. (NASDAQ: EXEL). Free technical research on ACHN, NVAX, DNDN and EXEL can be downloaded upon signing up at:
3 Reasons to Buy Medivation Inc.
George Budwell, The Motley Fool - Motley Fool - Mon Jul 07, 3:30PM CDT
The biotech industry has ballooned in terms of market value over the past two years. As a result, we have seen dozens of IPOs, creating a diverse population of companies that can be quite a challenge to follow in their entirety. So it's not...
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/465jcl/transitional_cell) has announced the addition of the "Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Amgen Inc. - Sanofi - Daiichi Sankyo Company, Limited - Novartis AG - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Dendreon Corporation - Cadila Pharmaceuticals Ltd. For more information visit http://www.researchandmarkets.com/research/46...ional_cell
Is There Any Hope for Dendreon?
Alexander Maxwell, The Motley Fool - Motley Fool - Wed Jul 02, 4:01PM CDT
Dendreon Corporation shareholders have been on a rollercoaster over the past few years. Dendreon got their lead product Provenge approved for use in metastatic castration-resistant prostate cancer, but has been unable to profitably produce and...
